On Tuesday, Esperion Therapeutics Inc (NASDAQ: ESPR) was -4.95% drop from the session before settling in for the closing price of $1.82. A 52-week range for ESPR has been $1.58 – $3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 9.55% over the past five years. When this article was written, the company’s average yearly earnings per share was at 84.40%. With a float of $195.08 million, this company’s outstanding shares have now reached $195.44 million.
Let’s look at the performance matrix of the company that is accounted for 240 employees. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Esperion Therapeutics Inc stocks. The insider ownership of Esperion Therapeutics Inc is 0.99%, while institutional ownership is 66.15%. The most recent insider transaction that took place on Feb 19 ’25, was worth 446. In this transaction Chief Commercial Officer of this company sold 239 shares at a rate of $1.87, taking the stock ownership to the 159,759 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Financial Officer sold 11 for $1.86, making the entire transaction worth $20. This insider now owns 240,671 shares in total.
Esperion Therapeutics Inc (ESPR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 84.40% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
You can see what Esperion Therapeutics Inc (ESPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (NASDAQ: ESPR) saw its 5-day average volume 2.84 million, a negative change from its year-to-date volume of 4.15 million. As of the previous 9 days, the stock’s Stochastic %D was 34.92%. Additionally, its Average True Range was 0.12.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 6.36%, which indicates a significant decrease from 8.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.25% in the past 14 days, which was lower than the 87.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0843, while its 200-day Moving Average is $2.1828. Nevertheless, the first resistance level for the watch stands at $1.8200 in the near term. At $1.9100, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.9600. If the price goes on to break the first support level at $1.6800, it is likely to go to the next support level at $1.6300. Assuming the price breaks the second support level, the third support level stands at $1.5400.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
There are 197,035K outstanding shares of the company, which has a market capitalization of 340.87 million. As of now, sales total 116,330 K while income totals -209,250 K. Its latest quarter income was 51,630 K while its last quarter net income were -29,520 K.
